StockNews.AI
ABBV
StockNews.AI
1 min

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

1. AbbVie and Nxera reached an R&D milestone in neurological disease collaboration. 2. Nxera received a $10 million payment as part of their agreement. 3. The collaboration began in 2022; future milestones could total $1.2 billion. 4. This milestone reflects productive collaboration, aiming for novel neurological therapies. 5. Recognition of the payment will occur in Q3 2025.

6m saved
Insight
Article

FAQ

Why Bullish?

AbbVie's collaboration and milestone payments enhance their pipeline and investor confidence, similar to past successful collaborations that drove stock gains.

How important is it?

The partnership with Nxera indicates ongoing innovation and solidifies AbbVie's focus on neurological disease, directly affecting its market position.

Why Long Term?

The potential future milestones and novel therapies may significantly boost growth over time, like AbbVie's previous successes in expanding their portfolio.

Related Companies

NXRA
September 29, 2025 19:30 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. This current milestone relates to the identification of validated and differentiated ‘hit’ molecules against a neurology target. Under the terms of the agreement, Nxera is eligible to receive up to US$40 million in near-term research milestones, as well as further potential option, development and commercial milestones totalling up to US$1.2 billion, plus tiered royalties on global sales. This is the second milestone received in this collaboration, following the first milestone which was achieved in June 2024. Dr. Matt Barnes, Chief Scientific Officer and President of Nxera Pharma UK, said: “Reaching this second milestone highlights the continued productivity of our collaboration with AbbVie, and reflects the remarkable work of our teams in applying our NxWave™ platform to discover and advance novel molecules that modulate neurological disease targets. We are very proud of the progress achieved so far and look forward to continuing our work towards impactful new therapies for patients.” The milestone payment will be recognized in the third quarter of 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements

Related News